CytomX Therapeutics, Inc.
NASDAQ:CTMXBiotechnology
-$0.03 today
- Market cap
- $409.85M
- Beta
- 2.09
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.33
Volume 4.39M
Average 4.99M
CTMX Total Liabilities
Everything the company owes to creditors and other parties.
CytomX Therapeutics, Inc.NASDAQ: CTMX
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 46.3% from a year ago
Total liabilities stood at $39.41M at the end of Q1 FY2026, down 46.3% from a year earlier and down 25.0% from the prior quarter. Over 3 fiscal years it compounded at -46.7% a year.
Context
- Total liabilities amounted to 11.0% of total assets at the end of Q1 FY2026, down 63.6 pp from a year earlier.
- Total liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -46.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 52.56M USD
- Year-over-year change
- -56.6%
- 4-year CAGR
- -37.3%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 52.56M | -56.6% |
| FY2024 | 2024-12-31 | 120.99M | -51.5% |
| FY2023 | 2023-12-31 | 249.24M | -28.1% |
| FY2022 | 2022-12-31 | 346.64M | +2.0% |
| FY2021 | 2021-12-31 | 339.87M | — |
Total Liabilities vs competitors
How CTMX compares with its peers on the latest reported figures
- CTMX's Mar 2026 total liabilities of $39.41M is the 9th highest of the 10 companies compared; the peer median is $221.73M.
- Its year-over-year change of -46.3% is the lowest of 10, against a peer median of +10.8%.
- Total liabilities amounts to 11.0% of total assets for CTMX, versus a peer median of 54.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $918.16M | +1089.2% | -20.6% | 78.0% | |
| Mar 2026 | $507.87M | -0.6% | +7.4% | 174.2% | |
| Mar 2026 | $308.88M | -11.0% | +17.3% | 127.6% | |
| Aug 2026 | $226.99M | +51.1% | +9.7% | 19.0% | |
| Jun 2026 | $221.73M | -14.4% | +26.4% | 30.6% | |
| Mar 2026 | $196.68M | +35.2% | +10.9% | 90.3% | |
| Sep 2026 | $72.06M | +43.9% | +28.1% | 10.0% | |
| Dec 2025 | $42.91M | +10.8% | -14.8% | 54.8% | |
| Mar 2026 | $39.41M | -46.3% | -46.7% | 11.0% | |
| Mar 2026 | $33.03M | +0.8% | -9.0% | 51.4% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CTMX) | $221.73M | +10.8% | +9.7% | 54.8% | |
Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 205.53M | 193.65M | 17.17M | 38.05M | 12.67M |
| Short-term Investments | 99.7M | 0 | 157.34M | 62.57M | 124.39M |
| Net Receivables | 790K | 35.99M | 3.43M | 3.1M | 2.01M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 7.47M | 5M | 3.58M | 4.86M |
| Total Current Assets | 310.3M | 237.1M | 182.94M | 107.31M | 143.92M |
| Property, Plant & Equipment (Net) | 25.32M | 21.02M | 16.18M | 10.6M | 4.7M |
| Goodwill | 949K | 949K | 949K | 949K | 949K |
| Intangible Assets | 1.02M | 875K | 729K | 583K | 438K |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.82M | 944K | 1M | 1.09M | 1.56M |
| Total Non-current Assets | 29.11M | 23.79M | 18.86M | 13.23M | 7.65M |
| Total Assets | 339.41M | 260.89M | 201.79M | 120.53M | 151.57M |
| Account Payables | 2.82M | 2.81M | 1.46M | 1.09M | 1.3M |
| Short-term Debt | 0 | 0 | 0 | 0 | 4.24M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 40.82M | 121.27M | 132.27M | 67.2M | 26.88M |
| Other Current Liabilities | 0 | 0 | 9.44M | 0 | 5.99M |
| Total Current Liabilities | 77.87M | 152.61M | 155.91M | 85.77M | 46.62M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 243.94M | 180.06M | 80.05M | 26.86M | 1.59M |
| Other Non-current Liabilities | 0 | 0 | 3.89M | 4.12M | 4.35M |
| Total Non-current Liabilities | 262M | 194.03M | 93.33M | 35.22M | 5.94M |
| Total Liabilities | 339.87M | 346.64M | 249.24M | 120.99M | 52.56M |
| Common Stock | 1K | 1K | 1K | 1K | 2K |
| Retained Earnings | (623.56M) | (722.88M) | (723.45M) | (691.58M) | (711.95M) |
| Accumulated OCI | (242K) | 10K | 95K | 27K | 111K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (459K) | (85.75M) | (47.45M) | (456K) | 99.01M |
| Total Debt | 21.67M | 18.06M | 13.97M | 9.39M | 4.24M |
| Net Debt | (183.86M) | (175.59M) | (3.2M) | (28.67M) | (8.43M) |
CytomX Therapeutics, Inc.
NASDAQ:CTMX
Intrinsic Alpha fair value
Locked
Current Price
$1.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.